{"id":"W2795488377","doi":"10.1016/s1470-2045(18)30146-3","title":"Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":349,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Daiichi-Sankyo; ArQule","keywords":"Medicine; Placebo; Sorafenib; Internal medicine; Hepatocellular carcinoma; Clinical endpoint; Population; Gastroenterology; Cirrhosis; Adverse effect; Intention-to-treat analysis; Phases of clinical research; Clinical trial; Surgery; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001067799,0.0002345129,0.003366042,0.0002506624,0.00008985207,0.000001590635,0.0001943084,0.0001586684,0.000510328],"category_scores_gemma":[0.0002115433,0.0001368439,0.0004972428,0.0003818075,0.0004615981,0.00002409531,0.00003792028,0.0001137827,0.000007245584],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006253946,"about_ca_system_score_gemma":0.0002017762,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005393525,"about_ca_topic_score_gemma":0.000142031,"domain_scores_codex":[0.9976465,0.0008519011,0.0006739597,0.0003629529,0.0001087844,0.0003559238],"domain_scores_gemma":[0.9966084,0.001872683,0.0005540652,0.0006312765,0.0002690181,0.00006457918],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8091602,0.007337745,0.0308739,0.00007555883,0.01152295,0.00009775861,0.005245002,0.00002643163,0.1305982,0.0002858609,0.0001414321,0.004634953],"study_design_scores_gemma":[0.8218266,0.08668678,0.01759098,0.00001366598,0.01866922,0.00003274378,0.0008810562,0.003516294,0.04846993,0.0002997302,0.001833616,0.0001793137],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937124,0.0002916287,0.0005065179,0.0003417134,0.0002069481,0.004218834,0.0001717945,0.00002123155,0.0005289509],"genre_scores_gemma":[0.9967703,0.00003236203,0.00108816,0.0002344765,0.0004649196,0.000730096,0.00009990105,0.00001594125,0.0005638466],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08212828,"threshold_uncertainty_score":0.5587733,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07760832321810575,"score_gpt":0.3859511444927207,"score_spread":0.308342821274615,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}